Investigation of malignant hyperthermia susceptibility in Denmark

Danish Medical Bulletin

Volumn 43, Issue 2, 1996, Pages 111-125

  Ørding, Helle ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Nordsjællands Hospital Hillerød   (Denmark)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DILTIAZEM; HALOTHANE; NIFEDIPINE; PROPRANOLOL; SALBUTAMOL; SUXAMETHONIUM; VERAPAMIL;

DENMARK; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; REVIEW;

ANIMALS; DENMARK; DISEASE SUSCEPTIBILITY; HUMANS; MALIGNANT HYPERTHERMIA;

EID: 0029962775     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Haudecoeur G, Reyfort GH, Dupuis BA. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia. Br. J. Anaesth. 1990, 64: 64-66.
2. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Reyfort H, Cordonnier C, Haudecoeur G. Effects of calcium-free solution, calcium antagonists, and the calcium agonist BAY 8644 on mechanical responses of skeletal muscle from patients susceptible to malignant hyperthermia, Anesthesiology 1991; 75: 413-419
3. Allen GC, Rosenberg H, Fletcher JE. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. Anesthesiology 1990; 72: 619-622.
4. Bendixen D, Ørding H. Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia. Acta Anaesthesiol. Scand. 1990; 34: 658-661 (VII).
5. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Canad. Anaesth. Soc. J. 1970, 17: 293-315.
6. Britt BA, Scott E, Frodis W, Clements M-J, Endrenyi L. Dantrolene - in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle Can. Anaesth. Soc. J. 1984; 31: 130-154.
7. Carroll JB. Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinylcholine. Anesthesiology 1987; 67: 559-561.
8. Cohen MM, Cameron CB, Duncan PG. Pediatric anesthesia morbidity and mortality in the perioperative period. Anesth. Analg. 1990; 70: 160-167.
9. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet 1960; 2: 45.
10. Deufel T, Golla A, Iles D, Meindl A, Meitinger T, Schindelhauer D, DeVries A, Pongratz D, MacLennan DH, Johnson KJ, Lehmann-Horn F. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am. J. Hum. Genet. 1992; 50: 1151-1161.
11. Donlon JV, Newfield P, Sreter F, Ryan JF. Implications of masseter spasm after succinylcholine. Anesthesiology 1978; 49: 298-301.
12. Ellis FR, Harriman DGF, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br. J. Anaesth. 1971; 43: 721-722.
13. Ellis FR, Harriman DGF. A new screening test for susceptibility to malignant hyperpyrexia. Br. J. Anaesth. 1973; 45: 638-639.
14. Ellis FR, Clarke IMC, Appleyard TN. Dinsdale RCW. Malignant hyperpyrexia induced by nitrous oxide and treated with dexamethasone. Br. Med J. 1974; 4: 270-271.
15. Ellis FR, Harriman DGF, Currie S, Cain PA. Screening for malignant hyperthermia in susceptible patients. In: Aldrete JA, Britt BA (eds.). Second international symposium on malignant hyperthermia. New York: Grune & Stratton, 1978, 273-285.
16. Ellis FR, Halsall PJ. Malignant hyperpyrexia. Br. J. Hosp. Med. 1980; 24: 318-327.
17. Ellis FR, Halsall PJ. Suxamethonium spasm; a differential diagnostic conundrum. Br. J Anaesth. 1984; 56: 381-384.
18. European MH Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br. J. Anaesth. 1984; 56: 1267-1269.
19. European MH Group. Laboratory diagnosis of malignant hyperpyrexia sus-ceptibility (MHS). Br. J Anaesth. 1985; 57: 1038.
20. Fagerlund T, Islander G, Ranklev E, Harbitz I, Hauge JG, Møkleby E, Berg K. Genetic recombination between malignant hyperthermia and calcium release channel in skeletal muscle. Clin. Genet. 1992; 41: 270-272.
21. Fishbein WN, Muldoon SM, Deuster PA, Armbrustmacher VW. Myoadenylate deaminase deficiency and malignant hyperthermia susceptibility: is there a relationship? Biochem. Med. 1985; 34: 344-354.
22. Fletcher JE, Rosenberg H. In vitro interaction between halothane and succinylcholine in human skeletal muscle: implications for malignant hyperthjermia and masseter muscle rigidity. Anesthesiology 1985; 63: 190-194.
23. Flewellen EU, Nelson TE. Masseter spasm induced by succinylcholine in children: contracture testing for malignant hyperthermia: report of six cases. Can. Anaesth. Soc. J. 1982; 29: 42-49.
24. Fujii J, Otsu K, Zorzato F, De Leon S, Khanna Vk, Weiler JE, O'Brien PJ, MacLennan DH. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-451.
25. Gallant EM, Fletcher TF, Goettl VM, Rempel WE. Porcine malignant hyperthermia: cell injury enhances halothane sensitivity of biopsies. Muscle & Nerve 1986; 9: 174-184.
26. Galloway GJ, Denborough MA. Suxamethonium chloride and malignant hyperpyrexia Br. J. Anaesth. 1986; 58: 447-450.
27. Gillard EF, Otsu K, Fujii J, Khanna VK, De Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991; 11: 751-755.
28. Gillard EF, Otsu K, Fujii J, Duff C, De Leon S, Khanna VK, Britt BA, Worton RG, MacLennan DH Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 1992; 13: 1247-1254.
29. Gronert GA, Theye RA. Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes. Anesthesiology 1976; 44: 36-43.
30. Gronert GA. Contracture resposes and energy stores in quadriceps muscle from humans age 7-82 years. Human Biology 1980; 52: 43-51.
31. Gronert GA, Mott J, Lee J. Aetiology of malignant hyperthermia. Br. J. Anaesth. 1988; 60: 253-267.
32. Hackl W, Mauritz W, Winkler M, Sporn P, Steinbereithner K. Anaesthesia in malignant hyperthermia-susceptible patients without dantrolene prophylaxis: a report of 30 cases. Acta Anaesthesiol. Scand. 1990a ; 34: 534-537.
33. Hackl W, Mauritz W, Schemper M, Winkler M, Sporn P, Steinbereithner K. Prediction of malignant hyperthermia susceptibility, statistical evaluation of clinical signs. Br. J. Anaesth. 1990b; 64: 425-429
34. Halsall PJ, Ellis FR. A screening test for the malignant hyperpyrexia phenotype using suxamethonium-induced contracture of muscle treated with caffeine, and its inhibition by dantrolene. Br. J. Anaesth. 1979; 51: 753-756.
35. Halsall PJ, Cain PA, Ellis FR. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized. Br. J. Anaesth. 1979; 51: 949-954.
36. Harrison GG, Saunders SJ, Biebuyck JF, Hickman R, Dent DM, Weaver V, Terblanche J Anaesthetic- induced malignant hyperpyrexia and a method for its prediction. Br. J. Anaesth. 1969; 41: 844-855
37. Healy JM, Heffron JJA, Lehane M, Bradley DG, Johnson K, McCarthy TV. Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers. Br. Med. J. 1991; 303: 1225-1228.
38. Heiman-Patterson T, Fletcher JE, Rosenberg H, Tahmoush AJ. No relationship between fiber type and halothane contracture test results in malignant hyperthermia. Anesthesiology 1987; 67: 82-84.
39. Heytens L, Heffron JJA, Camu F. The caffeine contracture test for malignant hyperthermia: caffeine citrate, caffeine benzoate or caffeine free base? Acta Anaesthesiol. Scand. 1991; 35. 541-544.
40. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br. J. Anaesth. 1991; 66: 611-613.
41. Iles DF, Segers B, Heytens L, Sengers RCA, Wieringa B. High-resolution physical mapping of four microsatellite repeat markers near the RYR1 locus on chromosome 19q13.1 and apparent exclusion of the MHS locus from this region in two malignant hyperthermia susceptible families. Genomics 1992; 14. 749-754.
42. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993; 79: 5-9.
43. Islander G, Ranklev Twetman E. Anaesthesia to the malignant hyperthermia negative (MHN) patient. Neurol. Sci. 1990; 98: S523 (abstract).
44. Iwatsuki N, Koga Y, Amaha K. Calcium channel blocker for treatment of malignant hyperthermia. Anesth. Analg. 1983; 62: 861-862.
45. Jacquot C, Stieglitz P, Kozak-Reiss G, Krivosic-Horber R, Laxenaire MC, Lienhart A, Nivoche Y. Recensement des cas francais d'hyperthermie maligne peranesthésique. Mise a jour. Ann. Fr. Anesth. Réanim. 1988; 7: 524-534.
46. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; 2: 895-898.
47. Kalow W, Britt BA, Richter A. The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can. Anaesth. Soc. J. 1977; 24: 678-694
48. Kikuchi H, Morio M, Shinozaki M, Ishihara S. Statistical considerations of malignant hyperthermia in Japan. In: Aldrete JA, Britt BA (eds.). Second international symposium on malignant hyperthermia. New York: Grune & Stratton, 1978: 483-498.
49. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia; a multicenter study. Anesthesiology 1982; 56: 254-262.
50. Kosko JR, Brandom BW, Chan KH. Masseter spasm and malignant hyperthermia: a restrospective review of a hospital-based pediatric otolaryngology practice. Int. J. Otolaryng. 1992; 23: 45-50.
51. Larach MG, Rosenberg H, Larach DR, Broennle AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology 1987; 66: 547-550.
52. Larach MG. Standardization of the halothane caffeine muscle contracture test. Anesth. Analg. 1989; 69: 511-515.
53. Larach MG, Landis JR, Bunn JS, Diaz M, The North American Malignant Hyperthermia Registry. Prediction of malignant hyperthermia susceptibility in low-risk subjects. Anesthesiology 1992a, 76: 16-27.
54. Larach MG, Landis JR, Shirk SJ, Diaz M, The North American Malignant Hyperthermia Registry. Prediction of malignant hyperthermia susceptibility in man: improving sensitivity of the caffeine halothane contracture test. Anesthesiology 1992b; 77: A1052.
55. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ørding H, Rosenberg H, Waud BE, Wedel DJ. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779.
56. Leary NP, Ellis FR. Masseteric muscle spasm as a normal response to suxamethonium. Br. J. Anaesth. 1990; 64: 488-492.
57. Lehmann-Horn F, Iaizzo PA. Resealed fiber segments for the study of the pathophysiology of human skeletal muscle. Muscle and Nerve 1990; 13: 222-231.
58. Lenzen C, Roewer N, Rumberger E, Schulte am Esch J. Ryanodin-induzierte Kontrakturen zur Diagnose der Maligne-Hyperthermie- Veranlagung. Anásthesiol. Intensivmed. Notfallsmed. Schmerzther. 1991; 26: 459-463.
59. Lerman J. Controversies in paediatric anaesthesia. Can. J. Anaesth. 1988; 35: S18-S22.
60. Leslie GC, MacLachlan DC. Comments on isometric twitch tension responses of human muscle biopsy challenged in vitro with caffeine and halothane Br. J. Anaesth. 1976, 48: 1122.
61. Littleford JA, Patel LR, Bose D, Cameron CB, McKillop C. Masseter muscle spasm in children: implications of continuing the anesthetic. Anesth. Analg. 1991; 72: 151-160.
62. Louis CF, Zualkernan K, Roghair T, Mickelson JR. The effects of volatile anaesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 1992; 77: 114-125.
63. Ludvigsen J. Examination of the socalled "muscular degeneration" in hogs. Report no. 272 from the Danish Agricultural Research Laboratory, Copenhagen, 1954.
64. Mauritz W, Sporn P, Steinbereithner K. Maligne Hyperthermie in Österreich. Anaesthesist 1986; 35: 639-650.
65. Melton A, Martucci RW, Kien ND, Gronert GA. Malignant hyperthermia in humans - standardization of contracture testing protocol. Anesth. Analg. 1989; 69. 437-443.
66. Mitsumoto H, DeBoer GE, Bunge G, Andrish JT, Tetzlaff JE, Cruse RP. Fiber-type specific caffeine sensitivities in normal human skinned muscle fibers. Anesthesiology 1990; 72: 50-54.
67. Moschcowitz AV. Post-operaive heatstroke. Surg. Gynec. Obstet. 1916; 23: 443-451.
68. Moulds RFW, Denborough MA. Biochemical basis of malignant hyperpyrexia. Br. Med. J. 1974; 2: 241-244.
69. Moulds RFW, Denborough MA. A study of the action of caffeine, halothane, potassium chloride and procaine on normal human skeletal muscle. Clin. Exp. Pharmacol. Physiol. 1974; 1: 197-209.
70. Nelson TE, Denborough MA. Studies on normal human skeletal muscle in relation to the pathopharmacology of malignant hyperpyrexia. Clin. Exp. Pharmacol. Physiol. 1977; 4: 315-322.
71. Nelson TE, Flewellen EH. Rationale for dantrolene versus procainamide for treatment of malignant hyperthermia. Anesthesiology 1979; 50: 118-122.
72. Nelson TE, Flewellen EH, Gloyna DF. Spectrum of susceptibility to malignant hyperthermia - diagnostic dilemma. Anesth. Analg. 1983, 62: 545-552.
73. Okumura F, Crocker BD, Denborough MA. Identification of susceptibility to malignant hyperthermia in swine. Br. J. Anaesth. 1979; 51: 171-176.
74. Ørding H, Ranklev E, Fletcher R Investigation of malignant hyperthermia in Denmark and Sweden. Br. J. Anaesth. 1984; 56; 1183-1190 (I).
75. Ørding H. Incidence of malignant hyperthermia in Denmark. Anesth. Analg 1985; 64: 700-704 (II).
76. Ørding H, Skovgaard L T. In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests. Acta Anaesthesiol. Scand. 1987; 31: 458-461 (III).
77. Ørding H, Skovgaard L T. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium, and caffeine-suxamethonium. Acta Anaesthesiol. Scand. 1987; 31: 462-465 (IV).
78. Ørding H. Diagnosis of susceptibility to malignant hyperthermia in man. Br. J. Anaesth. 1988; 60: 287-302.
79. Ørding H, Hansen U, Skovgaard LT. Age, fiber type composition and in vitro contracture responses in human malignant hyperthermia. Acta Anaesthesiol. Scand. 1988; 32: 121-124 (V).
80. Ørding H. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle. Acta Anaesthesiol. Scand. 1989; 33: 405-408 (VI).
81. Ørding H, Bendixen D. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Eur. J. Anaesth. 1992; 9: 367-376 (VIII).
82. Ørding H, Hedengran A M, Skovgaard L T. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol. Scand. 1991; 35: 711-716 (IX).
83. Plumley MH, Bevan JC, Saddler JM, Donati F, Bevan DR. Dose-related effects of succinylcholine on the adductor pollicis and masseter muscles in children. Can. J. Anaesth. 1990; 37: 15-20.
84. Pollock RA, Britt BA. Malignant hyperthermia in the head and neck surgery patient: an update and review. Laryngoscope 1983; 93: 318-325.
85. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ørding H, Bendixen D, Mortier W, Linz U, Muller CR, McCarthy TV. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genetics 1993; 5: 51-55.
86. Ranklev E, Fletcher R, Blomquist S. Static versus dynamic in vitro tests in the diagnosis of malignant hyperthermia susceptibility. Br. J. Anaesth. 1986; 58: 646-648.
87. Riegelman RK, Hirsch R. Studying a study and testing a test. 2nd ed. Boston: Little, Brown and Company. 1989: 127-183.
88. Rosenberg H, Reed S. In vitro contracture tests for susceptibility to malignant hyperthermia, Anesth. Analg. 1983; 62: 415-420.
89. Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesth. Analg. 1986; 65: 161-164.
90. Rosenberg H. Clinical presentation of malignant hyperthermia. Br. J. Anaesth. 1988; 60. 268-273.
91. Schwartz L, Rockoff MA, Koka BV. Masseter spasm with anesthesia: in-cidence and implications. Anesthesiology 1984; 61: 772-775.
92. Short CE, Paddleford RR. Malignant hyperthermia in the dog. Anesthesiology 1973; 39: 462-463.
93. Siegel S. Nonparametric statistics for the behavioral sciences. International student edition. McGraw-Hill. Kogakusha, 1956.
94. Smith CE, Saddler JM, Bevan JC, Donati F, Bevan DR. Pretreatment with non-depolarizing neuromuscular blocking agents and suxamethonium-induced increases in resting jaw tension in children. Br. J. Anaesth. 1990; 64: 577-581.
95. Van Der Spek AFL, Fang WB, Ashton-Miller JA, Stohler CS, Carlson DS, Schork MA. The effects of succinylcholine on mouth opening. Anesthesiology 1987; 67: 459-465.
96. Van Der Spek AFL, Fang WB, Ashton-Miller JA, Stohler CS, Carlson DS, Schork MA. Increased masticatory muscle stiffness during limb muscle flaccidity associated with succinylcholine administration. Anesthesiology 1988; 69: 11-16.
97. Van Der Spek AFL, Reynolds PI, Fang WB, Ashton-Miller JA, Stohler CS, Schork MA. Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants. Br. J. Anaesth. 1990; 64: 21-27.
98. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, Britt BA, Brownell KW, MacLennan DH. A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genetics 1993; 5: 46-50.